Influenza virus vaccine liposomal - Crucell

Drug Profile

Influenza virus vaccine liposomal - Crucell

Alternative Names: InfectoVac Flu; Inflexal V; Invivac; Isiflu V; Viroflu

Latest Information Update: 27 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Berna Biotech
  • Developer Crucell
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Influenza virus infections

Most Recent Events

  • 18 Oct 2013 Isconova has been acquired by Novavax
  • 06 Sep 2013 Isconova is now called Novavax AB
  • 01 Aug 2013 Crucell completes a phase III trial in Influenza virus infections (prevention; 2013/2014 season influenza vaccine) in Switzerland (NCT01893177)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top